Navigation Links
Edison Pharmaceuticals Receives Commendation From the City of San Jose
Date:7/6/2008

Mayor Chuck Reed recognizes contribution to city and children with rare

diseases

SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today the receipt of a commendation from the City of San Jose, acknowledging the company's contributions in fighting rare childhood diseases. The commendation recognizes "Edison for outstanding achievements in developing drugs for unmet medical need, and its commitment to public-private partnership, and extend our best wishes for many years of success in positively impacting the lives of children and individuals with mitochondrial diseases in America and throughout the world."

Mayor Chuck Reed and Councilmember Forrest Williams presented the commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th, 2008 at City Hall. "Since starting operations at the San Jose BioCenter in January 2006, Edison Pharmaceuticals has helped to make San Jose a center of life science technology. Edison is doing a remarkable job by focusing its R&D efforts on discovering a treatment for mitochondrial diseases -- that impair energy metabolism, and for which there exist no drugs," said Mayor Chuck Reed. "I congratulate Edison on achieving high performance standards and for the commitment of its founder Dr. Guy Miller and his team to improving the lives of children throughout the world."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon Valley California at the San Jose Biocenter, is focused on developing drugs for rare diseases that impair energy metabolism. Edison possesses a technology platform and specialized knowledge in redox therapeutics -- pivotal to targeting genetic defects in the mitochondria. The Company's initial focus is on inherited diseases of the mitochondrial respiratory chain. The company is leveraging insights derived from those studies to pursue other diseases that share common mechanisms, such as Huntington's disease and diseases of aging. Edison has obtained substantial peer-reviewed grants from multiple foundations and the National Institutes of Health.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edison Innovation Fund Helps Tris Pharma Expand
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... and London UK (PRWEB) , ... August 10, 2017 , ... ... will host a new educational webinar to demonstrate how Good Clinical Practice ... contracts, and site documents. In addition the webinar will discuss the importance of GCP ...
(Date:8/10/2017)... FL (PRWEB) , ... August 10, 2017 , ... ... that the stock market news outlet had initiated coverage on Next Group Holdings, ... growing and underserved consumer markets geared toward those that cannot engage in traditional ...
(Date:8/10/2017)... 10, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife" or the "Company"), today reported operational highlights and ... June 30, 2017. Revenue from biopreservation media ... in the second quarter of 2017, an increase of ...
(Date:8/8/2017)... ... August 08, 2017 , ... This webinar, ... Virtual Event, will discuss Phase Analysis Light Scattering (PALS) and Raman spectroscopy methods ... used to assess vaccine product quality and consistency regarding particle size, zeta potential ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):